ECG vs GATX

ECG exhibits a stable financial foundation with a Piotroski F-Score of 6/9 and impressive growth metrics, including 60.2% YoY earnings growth. However, the stock is significantly overvalued, trading at $136.06—well above its Graham Number ($33.13) and Intrinsic Value ($116.53). While profitability is strong with an ROE of 38.34%, the technical trend is heavily bearish (10/100), suggesting the recent 232% one-year rally may have peaked. The valuation premium is high, and the current price exceeds the analyst target of $131.50.

GATX exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and financial stability. While the stock trades at a premium to its defensive Graham Number ($126.27), it remains significantly undervalued relative to its growth-based intrinsic value of $269.04, supported by an exceptional PEG ratio of 0.64. Strong double-digit earnings growth (25.8% YoY) and high operating margins (30.96%) outweigh the bearish insider sentiment and current technical weakness. The company's liquidity position is exceptional, as evidenced by a current ratio of 11.03, mitigating the risks associated with its high debt-to-equity ratio.